An observational study in Chronic Pancreatitis, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 1 site in Italy. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by Associazione Italiana per lo Studio del Pancreas · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ITARECIPE is a multicenter national registry designed to study the diagnosis and evolution of Chronic Pancreatitis
Chronic pancreatitis (PC) is a relatively rare disease (45/100,000 population) in Italy, with heterogeneous aetiology, clinical history and treatment.
Patients need to be treated by different specialists, but almost always the gastroenterologist is central in diagnosis and treatment.
The study will be the first National Registry, prospective and will collect data on the history of the disease and its outcomes.
Data will be collected through an electronic data collection form (e-CRF) that the Sponsor (AISP) will make available to the Participating Centres.
Patients enrolled will be both new diagnoses or follow-up visits of patients with a diagnosis already made no more than 1 year before the signing of informed consent for the study in question: only data on the diagnosis and follow-up visits prior to the signing of the informed consent will be collected retrospectively (no more than one year).
Data from patients visited in the Centres included in the study will be collected prospectively.
In addition to the first visits, data will also be collected on follow-up visits that are scheduled according to the clinical need of each patient, which differ according to the stage of the disease
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.
Browse Pancreatitis, Chronic studies →Associazione Italiana per lo Studio del Pancreas is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Disease Progression
The collection of data on disease progression in terms of the need for medical, endoscopic or surgical therapy, the risk of pancreatic exo-endocrine failure and the risk of developing pancreatic and extrapancreatic complications and death.
Time frame: 5 years
Started Oct 2022 (actual). Primary completion is estimated for Dec 2027, 62 months after the start.
Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 62 months is below that.
Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Associazione Italiana per lo Studio del Pancreas